Global Human Embryonic Stem Cell Laws and Policies and Their Influence on Stem Cell Tourism
By Nishakanthi Gopalan et al.,
Biotechnology Law Report
| 10. 09. 2018
Abstract
Stem cell (SC) technology has spurred many debates among experts which highlight both the deficiency of current regulation and the growing need for better oversight. The benefit of better regulating SC technology is easily understood by studying the variety of laws and policies available. Previous compilations, last published in 2009, are outdated, calling for an update. Therefore, this study aims to bring up to date the laws and policies relating to human embryonic stem cells (HESC) and to identify emerging trends in regulation. The review of numerous legal documents, including bills and legislation, accessed through official government portals, found that all developed countries have sound legislation promoting research. While some developed nations have gaps within their otherwise-sound regulation, a more pressing issue is growing travel for treatment (“SC tourism”) to developing and under-developed countries where SC technology is under- or unregulated. Therefore, SC tourism is no longer a country issue; rather, it is a universal dilemma requiring international effort for a resolution.
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...